Author

Simon Hirschmann 1

1 University of Erlangen-Nürnberg,Erlangen,Germany

EFFECTIVENESS, IMMUNOGENICITY, SAFETY AND PHARMACOECONOMIC ASPECTS FOLLOWING A SWITCH FROM REFERENCE INFLIXIMAB TO THE BIOSIMILAR SB2 IN INFLAMMATORY BOWEL DISEASE PATIENTS: A 6 MONTHS PROSPECTIVE COHORT STUDY

Sarah Fischer, Entcho Klenske, Heike Schmitt, Francesco Vitali, Simon Hirschmann, Franz Koch, Andreas Ramming, Sebastian Zundler, Sabine Krebs, Frank Dörje, Daniel Nagore, Sebastian Meyer, Wolfgang Uter, Markus F. Neurath, Raja Atreya

EXPANSION OF IL-23 RECEPTOR BEARING TNFR2+ T CELLS DRIVES RESISTANCE TO ANTI-TNF THERAPY IN CROHN`S DISEASE

Heike Schmitt, Ulrike Billmeier, Walburga Dieterich, Timo Rath, Simon Hirschmann, Clemens Neufert, Kai Hildner, Maximilian J. Waldner, Jonas Mudter, Tino Münster, Markus F. Neurath, Raja Atreya

SUBMUCOSAL INJECTION OF THE RNA OLIGONUCLEOTIDE STNM01 IN ACTIVE ULCERATIVE COLITIS INDUCES MUCOSAL HEALING AND REVERSES TISSUE REMODELING

Raja Atreya, Tanja Kühbacher, Maximilian J. Waldner, Simon Hirschmann, Oliver Drvarov, Raed Abu Hashem, Christian Maaser, Torsten Kucharzik, Johanna Dinter, Jessica Mertens, Christoph Schramm, Babett Holler, Joachim Mössner, Kenji Suzuki, Naoyuki Yokoyama, Shuji Terai, Hiroyuki Yoneyama, Hitoshi Asakura, Toshifumi Hibi,

Item 1 - 3 / 3
1